{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:48:26Z","timestamp":1791658106965,"version":"4.3.4"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":152,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.prdoa.2026.100461","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:10:55Z","timestamp":1780531855000},"page":"100461","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Glucagon-like peptide-1 receptor agonists in movement disorders: From Parkinson's disease to the broader spectrum \u2014 Mechanisms, evidence, and future directions"],"prefix":"10.1016","volume":"15","author":[{"given":"Ahmed","family":"Dahshan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa Ibrahim Mahfouz","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaimaa I.","family":"El-Jaafary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Al Yamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.prdoa.2026.100461_bb0005","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s00415-026-13703-6","article-title":"A phenomenological approach to spastic movement disorders: an international expert panel consensus","volume":"273","author":"Biering-S\u00f8rensen","year":"2026","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.prdoa.2026.100461_bb0010","first-page":"221","article-title":"Spectrum of movement disorders in mitochondrial diseases","volume":"4","author":"Musumeci","year":"2020","journal-title":"J. Translational Genetics Genomics."},{"issue":"4","key":"10.1016\/j.prdoa.2026.100461_bb0015","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s40120-025-00724-y","article-title":"Are glucagon-like peptide-1 (GLP-1) receptor agonists central nervous system (CNS) penetrant: a narrative review","volume":"14","author":"West","year":"2025","journal-title":"Neurol. Ther."},{"issue":"1","key":"10.1016\/j.prdoa.2026.100461_bb0020","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12929-024-01090-x","article-title":"Role of glucagon-like peptide-1 receptor agonists in Alzheimer\u2019s disease and Parkinson\u2019s disease","volume":"31","author":"Hong","year":"2024","journal-title":"J. Biomed. Sci."},{"issue":"16","key":"10.1016\/j.prdoa.2026.100461_bb0025","article-title":"Research on the effects of GLP-1 receptor agonists in treating cognitive dysfunction and gait disorders in elderly patients with diabetes","author":"Yang","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.prdoa.2026.100461_bb0030","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1001\/jamaneurol.2018.4304","article-title":"Utility of neuronal-derived exosomes to examine molecular mechanisms that affect motor function in patients with Parkinson disease: a secondary analysis of the exenatide-PD trial","volume":"76","author":"Athauda","year":"2019","journal-title":"JAMA Neurol."},{"issue":"17","key":"10.1016\/j.prdoa.2026.100461_bb0035","doi-asserted-by":"crossref","first-page":"9583","DOI":"10.3390\/ijms23179583","article-title":"Anti-inflammatory effects of GLP-1 receptor activation in the brain in neurodegenerative diseases","volume":"23","author":"Diz-Chaves","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prdoa.2026.100461_bb0040","doi-asserted-by":"crossref","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther. Adv. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.prdoa.2026.100461_bb0045","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3233\/JPD-181503","article-title":"Semaglutide is neuroprotective and reduces \u03b1-synuclein levels in the chronic MPTP mouse model of Parkinson\u2019s disease","volume":"9","author":"Zhang","year":"2019","journal-title":"J. Parkinsons Dis."},{"issue":"165","key":"10.1016\/j.prdoa.2026.100461_bb0050","article-title":"GLP-1\/GIP dual agonist tirzepatide alleviates mice model of Parkinson\u2019s disease by promoting mitochondrial homeostasis","volume":"14","author":"Tian","year":"2025","journal-title":"Int. Immunopharmacol."},{"issue":"2","key":"10.1016\/j.prdoa.2026.100461_bb0055","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1007\/s13311-021-01018-5","article-title":"Neuroprotection of exendin-4 by enhanced autophagy in a parkinsonian rat model of \u03b1-synucleinopathy","volume":"18","author":"Bu","year":"2021","journal-title":"Neurotherapeutics"},{"issue":"4","key":"10.1016\/j.prdoa.2026.100461_bb0060","doi-asserted-by":"crossref","DOI":"10.1172\/JCI194745","article-title":"The promise of GLP-1 receptor agonists for neurodegenerative diseases","volume":"136","author":"Athauda","year":"2026","journal-title":"J. Clin. Invest."},{"issue":"11","key":"10.1016\/j.prdoa.2026.100461_bb0065","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3390\/biology9110348","article-title":"The neurotrophic function of glucagon-like peptide-1 promotes human neuroblastoma differentiation via the PI3K-AKT axis","volume":"9","author":"Yang","year":"2020","journal-title":"Biology"},{"issue":"6","key":"10.1016\/j.prdoa.2026.100461_bb0070","article-title":"The effect of GLP-1 receptor agonists in pre-clinical rodent models of Parkinson\u2019s disease: a systematic review and meta-analysis","volume":"1","author":"Dahiya","year":"2022","journal-title":"Clin. Parkinsonism Related Disorders."},{"key":"10.1016\/j.prdoa.2026.100461_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2021.113693","article-title":"An extended release GLP-1 analogue increases \u03b1-synuclein accumulation in a mouse model of prodromal Parkinson\u2019s disease","volume":"341","author":"Bergkvist","year":"2021","journal-title":"Exp. Neurol."},{"issue":"13","key":"10.1016\/j.prdoa.2026.100461_bb0080","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","article-title":"Trial of lixisenatide in early Parkinson\u2019s disease","volume":"390","author":"Meissner","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"10103","key":"10.1016\/j.prdoa.2026.100461_bb0085","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"issue":"10479","key":"10.1016\/j.prdoa.2026.100461_bb0090","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0140-6736(24)02808-3","article-title":"Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson\u2019s disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial","volume":"405","author":"Vijiaratnam","year":"2025","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.prdoa.2026.100461_bb0095","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2025-112318","article-title":"Disease-modifying effect, safety and optimal dose of oral semaglutide tablets for patients with Parkinson\u2019s disease (MOST-ABLE study): protocol for a randomised, double-blind, placebo-controlled study","volume":"15","author":"Kimura","year":"2025","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.prdoa.2026.100461_bb0100","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S1474-4422(23)00378-2","article-title":"Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial","volume":"23","author":"McGarry","year":"2024","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.prdoa.2026.100461_bb0105","series-title":"A Phase II, Randomized, Double-Blinded, Placebo-Controlled Trial of Liraglutide in Parkinson\u2019s Disease","author":"Hogg","year":"2022"},{"key":"10.1016\/j.prdoa.2026.100461_bb0110","doi-asserted-by":"crossref","DOI":"10.1177\/17562864251372747","article-title":"GLP-1 receptor agonists in Parkinson\u2019s disease progression: a meta-analysis with trial sequential analysis of randomized controlled trials","volume":"18","author":"Tsai","year":"2025","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"5","key":"10.1016\/j.prdoa.2026.100461_bb0115","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/ana.70004","article-title":"Exenatide once weekly in the treatment of patients with multiple system atrophy","volume":"98","author":"Vijiaratnam","year":"2025","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/j.prdoa.2026.100461_bb0120","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.drudis.2016.01.013","article-title":"The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson\u2019s disease: mechanisms of action","volume":"21","author":"Athauda","year":"2016","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.prdoa.2026.100461_bb0125","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12868-016-0272-9","article-title":"The GLP-1 receptor agonists exendin-4 and liraglutide alleviate oxidative stress and cognitive and micturition deficits induced by middle cerebral artery occlusion in diabetic mice","volume":"17","author":"Li","year":"2016","journal-title":"BMC Neurosci."},{"issue":"1","key":"10.1016\/j.prdoa.2026.100461_bb0130","doi-asserted-by":"crossref","first-page":"8961","DOI":"10.1038\/s41598-018-27121-w","article-title":"Dual therapy with Liraglutide and ghrelin promotes brain and peripheral energy metabolism in the R6\/2 mouse model of Huntington\u2019s disease","volume":"8","author":"Duarte","year":"2018","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.prdoa.2026.100461_bb0135","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.3390\/ijms19092505","article-title":"GLP-1 analogue Liraglutide attenuates mutant huntingtin-induced neurotoxicity by restoration of neuronal insulin signaling","volume":"19","author":"Chang","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.prdoa.2026.100461_bb0140","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/acn3.70204","article-title":"Purkinje cell loss in essential tremor: collective data from 215 brains over a 21-year period","volume":"13","author":"Kerridge","year":"2026","journal-title":"Annals Clin. Translational Neurology."},{"issue":"135","key":"10.1016\/j.prdoa.2026.100461_bb0145","article-title":"Movement disorders related to antidiabetic medications: a real-world pharmacovigilance study","volume":"20","author":"Zhao","year":"2024","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.prdoa.2026.100461_bb0150","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.134221","article-title":"Exenatide induces frataxin expression and improves mitochondrial function in Friedreich ataxia","volume":"5","author":"Igoillo-Esteve","year":"2020","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.prdoa.2026.100461_bb0155","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3934\/Neuroscience.2025011","article-title":"Infantile neuroaxonal dystrophy: molecular mechanisms and pathogenesis of PLA2G6-associated neurodegeneration","volume":"12","author":"Gonz\u00e1lez-S\u00e1nchez","year":"2025","journal-title":"AIMS Neuroscience"},{"key":"10.1016\/j.prdoa.2026.100461_bb0160","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/jcpt.13225","article-title":"Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes","volume":"45","author":"Trujillo","year":"2020","journal-title":"J. Clin. Pharm. Ther."},{"issue":"1","key":"10.1016\/j.prdoa.2026.100461_bb0165","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2202-13-33","article-title":"Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis","volume":"13","author":"Hunter","year":"2012","journal-title":"BMC Neurosci."},{"issue":"253","key":"10.1016\/j.prdoa.2026.100461_bb0170","article-title":"Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: a revolution in the making?","volume":"1","author":"H\u00f6lscher","year":"2024","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.prdoa.2026.100461_bb0175","doi-asserted-by":"crossref","DOI":"10.1080\/21688370.2023.2292461","article-title":"Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer\u2019s and Parkinson\u2019s diseases","volume":"12","author":"Rhea","year":"2024","journal-title":"Tissue Barriers."},{"issue":"10","key":"10.1016\/j.prdoa.2026.100461_bb0180","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1172\/JCI75276","article-title":"The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss","volume":"124","author":"Secher","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.prdoa.2026.100461_bb0185","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133429","article-title":"Semaglutide lowers body weight in rodents via distributed neural pathways","volume":"5","author":"Gabery","year":"2020","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/j.prdoa.2026.100461_bb0190","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/14728222.2022.2079492","article-title":"Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson\u2019s disease","volume":"26","author":"Yang","year":"2022","journal-title":"Expert Opin. Ther. Targets"},{"issue":"2","key":"10.1016\/j.prdoa.2026.100461_bb0195","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.70037","article-title":"Association of GLP-1 receptor agonists with risk of suicidal ideation and behaviour: a systematic review and meta-analysis","volume":"41","author":"Bushi","year":"2025","journal-title":"Diabetes Metab. Res. Rev."},{"issue":"5","key":"10.1016\/j.prdoa.2026.100461_bb0200","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-047993","article-title":"Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson\u2019s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: the \u2018Exenatide-PD3\u2019study","volume":"11","author":"Vijiaratnam","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.prdoa.2026.100461_bb0205","article-title":"Next generation dual GLP-1\/GIP, GLP-1\/glucagon, and triple GLP-1\/GIP\/glucagon agonists: a literature review","volume":"28","author":"Wen","year":"2025","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"issue":"3","key":"10.1016\/j.prdoa.2026.100461_bb0210","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1677\/JOE-09-0132","article-title":"Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson\u2019s disease","volume":"202","author":"Kim","year":"2009","journal-title":"J. Endocrinol."},{"issue":"303","key":"10.1016\/j.prdoa.2026.100461_bb0215","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neuroscience.2015.06.054","article-title":"Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson\u2019s disease","volume":"10","author":"Liu","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.prdoa.2026.100461_bb0220","doi-asserted-by":"crossref","first-page":"177972","DOI":"10.1016\/j.ejphar.2025.177972","article-title":"The novel GLP-1\/GIP dual agonist DA3-CH is more effective than liraglutide in the MPTP mouse model of Parkinson\u2019s disease","volume":"5","author":"Feng","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.prdoa.2026.100461_bb0225","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.npep.2018.07.003","article-title":"Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson\u2019s disease mouse model","volume":"71","author":"Zhang","year":"2018","journal-title":"Neuropeptides"},{"issue":"1","key":"10.1016\/j.prdoa.2026.100461_bb0230","doi-asserted-by":"crossref","first-page":"10722","DOI":"10.1038\/s41598-018-28449-z","article-title":"Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson\u2019s disease","volume":"8","author":"Chen","year":"2018","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.prdoa.2026.100461_bb0235","doi-asserted-by":"crossref","first-page":"13825","DOI":"10.1038\/s41598-022-17338-1","article-title":"A GLP1 receptor agonist diabetes drug ameliorates neurodegeneration in a mouse model of infantile neurometabolic disease","volume":"12","author":"Poupon-Bejuit","year":"2022","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.prdoa.2026.100461_bb0240","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1172\/JCI68295","article-title":"Exenatide and the treatment of patients with Parkinson\u2019s disease","volume":"123","author":"Aviles-Olmos","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.prdoa.2026.100461_bb0245","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3233\/JPD-140364","article-title":"Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson\u2019s disease","volume":"4","author":"Aviles-Olmos","year":"2014","journal-title":"J. Parkinsons Dis."}],"container-title":["Clinical Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112526000411?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112526000411?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T17:50:28Z","timestamp":1791654628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590112526000411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":49,"alternative-id":["S2590112526000411"],"URL":"https:\/\/doi.org\/10.1016\/j.prdoa.2026.100461","relation":{},"ISSN":["2590-1125"],"issn-type":[{"value":"2590-1125","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-like peptide-1 receptor agonists in movement disorders: From Parkinson's disease to the broader spectrum \u2014 Mechanisms, evidence, and future directions","name":"articletitle","label":"Article Title"},{"value":"Clinical Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prdoa.2026.100461","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100461"}}